Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. We show 37 historical shares outstanding datapoints in our CRVS shares outstanding history coverage, used to compute CRVS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CRVS market cap history over the course of time is important for investors
interested in comparing CRVS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CRVS versus a peer is one thing; comparing
CRVS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CRVS can fluctuate over the course of history.
With this page we aim to empower investors researching CRVS by allowing them to research the CRVS market cap history. |
Free CRVS Email Alerts:
Video: The Importance of Market Cap
